SABCS 2021 Meeting News Preview - 11

Look deeper.
Know sooner.
Illuminate risk, monitor response, and detect
recurrence earlier with breakthrough technology
for high-risk breast cancer.
Signatera is a personalized, tumorinformed
molecular residual disease
(MRD) test that leverages dynamic
ctDNA measurements to help inform
cancer management.
Explore our innovative technology at SABCS booth #723
or visit us at Natera.com/know-breast-cancer
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com
Signatera has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test
has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.
© 2021 Natera, Inc. All Rights Reserved. SGN_AD_SABCS_20211018_NAT-8020505

https://www.natera.com/know-breast-cancer?utm_source=tristar&utm_medium=ad&utm_campaign=breast-cancer-launch http://www.natera.com

SABCS 2021 Meeting News Preview

Table of Contents for the Digital Edition of SABCS 2021 Meeting News Preview